X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/ocedurenone-kbp-5074-featured-at-asn-kidney-week-ocedurenone-is-a-potential-new-treatment-option-for-patients-with-uncontrolled-or-resistant-hypertension-and-advanced-ckd-301715194.html
https://www.globenewswire.com/news-release/2021/06/16/2248139/0/en/KBP-Biosciences-Announces-A-Greater-Than-10-mm-Hg-Systolic-Blood-Pressure-Reduction-in-The-BLOCK-CKD-Phase-2b-Study-of-KBP-5074-in-Advanced-Chronic-Kidney-Disease-Patients-with-Unc.html
https://www.clinicaltrialsarena.com/comment/kbp-biosciences-5074-blood-pressure/
https://www.globenewswire.com/fr/news-release/2020/12/07/2140535/0/en/KBP-Biosciences-Meets-Primary-Endpoint-for-BLOCK-CKD-Phase-2b-Study-of-KBP-5074-for-the-Treatment-of-Uncontrolled-Hypertension-in-Advanced-Chronic-Kidney-Disease-Patients.html
https://www.globenewswire.com/news-release/2020/10/22/2113242/0/en/KBP-Biosciences-Announces-Data-Presentation-at-the-American-Society-of-Nephrology-Annual-Meeting.html
https://www.globenewswire.com/news-release/2020/08/05/2073235/0/en/KBP-Biosciences-Doses-Final-Patient-in-BLOCK-CKD-Phase-2b-Study-of-KBP-5074.html
https://www.globenewswire.com/news-release/2020/06/29/2054664/0/en/KBP-Biosciences-Announces-Peer-Reviewed-Publication-of-Trial-Design-Manuscript-for-Ongoing-BLOCK-CKD-Phase-2b-Study-of-KBP-5074-in-Advanced-Chronic-Kidney-Disease-Patients-with-Unc.html
https://www.globenewswire.com/news-release/2020/05/21/2037036/0/en/KBP-Biosciences-KBP-5074-Appears-Well-Tolerated-in-a-single-dose-PK-Study-in-severe-Chronic-Kidney-Disease-CKD-patients-with-and-without-hemodialysis.html
https://www.globenewswire.com/news-release/2020/05/20/2036326/0/en/KBP-Biosciences-Completes-Enrollment-of-BLOCK-CKD-Phase-2b-Study-of-KBP-5074.html
Market Place
Share 
